These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 11225170)
1. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. O'Donnell DC; Chen NT; Piziak VK Am J Health Syst Pharm; 2001 Feb; 58(4):325-30. PubMed ID: 11225170 [No Abstract] [Full Text] [Related]
2. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study. Alemao E; Yin D; Sintonen H; Salomaa V; Jousilahti P Am J Cardiovasc Drugs; 2006; 6(5):349-55. PubMed ID: 17083270 [TBL] [Abstract][Full Text] [Related]
3. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Paragh G; Márk L; Zámolyi K; Pados G; Ofner P Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573 [TBL] [Abstract][Full Text] [Related]
4. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657 [TBL] [Abstract][Full Text] [Related]
5. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
6. Lipid attainment among patients newly treated with lipid-altering drugs. Hess G; Chang CL; Chung K Curr Med Res Opin; 2014 Sep; 30(9):1743-56. PubMed ID: 24889282 [TBL] [Abstract][Full Text] [Related]
7. The evolution of European guidelines: changing the management of cholesterol levels. Erhardt LR; Gotto A Atherosclerosis; 2006 Mar; 185(1):12-20. PubMed ID: 16309687 [TBL] [Abstract][Full Text] [Related]
8. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. Tomasik T; Jozwiak J; Windak A; Rygiel K; Mastej M; Smithson WH; Mathers N; Tomaszewski M; Kaess BM; Tykarski A; Konduracka E; Grzeszczak W; Lukas W Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):287-96. PubMed ID: 21450675 [TBL] [Abstract][Full Text] [Related]
9. Medicines for lowering cholesterol. Am Fam Physician; 2011 Sep; 84(5):561-2. PubMed ID: 21888307 [No Abstract] [Full Text] [Related]
10. [Cholesterol. On its significance in gerner practice]. Schönwandt M Z Allgemeinmed; 1974 Nov; 50(31):1399-401. PubMed ID: 4464666 [No Abstract] [Full Text] [Related]
11. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Willey VJ; Bullano MF; Shoetan NN; Gandhi SK Curr Med Res Opin; 2010 Jan; 26(1):121-8. PubMed ID: 19916706 [TBL] [Abstract][Full Text] [Related]
12. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Stender S; Schuster H; Barter P; Watkins C; Kallend D; Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130 [TBL] [Abstract][Full Text] [Related]
13. [Drug therapy of hypercholesterolemia]. Schwandt P; Richter WO Wien Klin Wochenschr; 1995; 107(18):544-8. PubMed ID: 7483641 [TBL] [Abstract][Full Text] [Related]